Skip to main content
Premium Trial:

Request an Annual Quote

Controversy, Drama, and Retracted Papers

A post at Biocurious examines the recent controversy surrounding work by Duke biochemist Homme Hellinga. Hellinga's 2004 Science paper reported on a computationally designed, biologically active enzyme and was retracted in February after SUNY Buffalo's John Richard could not reproduce the results (a 2007 Journal of Molecular Biology paper was also retracted).

Ross Anderson at Biocurious says there were definite flaws in the experimental design -- contamination had to be a problem. Hellinga blamed his graduate student for falsifying data, but Duke found Mary Dwyer innocent of fraud. An editorial in Nature says that Hellinga and Duke owe the scientific community an explanation. Anderson adds, "Every scientist has a commitment to honestly present their work and based on this we trust, for the most part, what we read in peer-reviewed journals. Break that trust and you will face the consequences."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.